Literature DB >> 27930821

Assessment of asymmetrical dimethylarginine metabolism in patients with critical illness.

Rawia A Ghashut1,2, Scott Blackwell3, Sylvia Ryan3, Laura Willox3, Donald C McMillan2, John Kinsella1, Dinesh Talwar3.   

Abstract

BACKGROUND: Critically ill patients experience metabolic disorders including hypercatabolic state and hyperglycaemia, and these are associated with poor outcome. Hyperglycaemia and asymmetrical dimethylarginine (ADMA) are reported to have significant influences on endothelial dysfunction. The aim of this study was to examine the relationship between plasma ADMA and related arginine metabolism in patients with critical illness. MATERIALS AND METHOSDS: Two venous blood samples (EDTA) (104 patients), on admission and follow-up sample in the last day in intensive care unit (ICU) (died or discharge sample median 7, interquartile range (IQR) 6-8, range 5-15). Plasma ADMA, arginine, homoarginine and SDMA were measured by high-performance liquid chromatography (HPLC). RESULT: ADMA (P < 0·01) and SDMA (P < 0·05) were elevated, and homoarginine was decreased (P < 0·05) in nonsurvivors and was directly associated with predicted mortality rate (P < 0·05 and P < 0·001), Sequential Organ Failure Assessment (SOFA) (P < 0·05, P < 0·001), ICU stay (P < 0·05, P < 0·001) and mortality (P < 0·01, P < 0·05). ADMA was directly associated with SDMA (P < 0·001), albumin (P < 0·05), ICU stay and mortality (P < 0·01). SDMA was directly associated with creatinine (P < 0·001) and Acute physiology and Chronic Health Evaluation II score (P < 0·001). In the follow-up measurements, there was a significant decrease in SOFA score (P < 0·01), homoarginine (P < 0·01), aminotransferase (P < 0·01), Laboratory Glucose (P < 0·01) and albumin (P < 0·01). In contrast, there was an increase in arginine (P < 0·01), ADMA (P < 0·01), ADMA:SDMA ratio (P < 0·01) and the norepinephrine administration (P < 0·01).
CONCLUSION: In the present longitudinal study, ADMA metabolism was altered in patients with critical illness and was associated with disease severity and mortality.
© 2016 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Arginine; asymmetrical dimethylarginine; critical illness; homoarginine; symmetrical dimethylarginine

Mesh:

Substances:

Year:  2017        PMID: 27930821     DOI: 10.1111/eci.12710

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  A Therapeutic Extracorporeal Device for Specific Removal of Pathologic Asymmetric Dimethylarginine from the Blood.

Authors:  Young Lee; Sarah M L Steinbach; David Basile; Jaipal Singh
Journal:  Blood Purif       Date:  2022-03-04       Impact factor: 3.348

2.  Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients.

Authors:  Juliane Hannemann; Paul Balfanz; Edzard Schwedhelm; Bojan Hartmann; Johanna Ule; Dirk Müller-Wieland; Edgar Dahl; Michael Dreher; Nikolaus Marx
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

Review 3.  A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach.

Authors:  Jaipal Singh; Young Lee; John A Kellum
Journal:  Crit Care       Date:  2022-08-12       Impact factor: 19.334

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.